Famotidine Injection is indicated in some hospitalized patients with pathological hypersecretory conditions or intractable ulcers, or as an alternative to the oral dosage forms for short term use in ...
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Famotidine Injection USP, 40 mg/4 mL (10 mg/mL) and 200 mg/20 mL (10 mg/mL) ...
The United States Food and Drug Administration (USFDA) has given Zydus Lifesciences Limited (formerly Cadila Healthcare Limited) final approval to market Famotidine Injection USP, 40 mg/4 mL (10 mg/mL ...
Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies is voluntarily recalling three lots (numbers 6133156, 6133194, ...
In the table of the release dated Nov 6, 2025, First Ship Date for Batch Number 6133388 should be 04/15/2025. FRESENIUS KABI ISSUES VOLUNTARY NATIONWIDE RECALL OF THREE LOTS OF FAMOTIDINE INJECTION, ...
FOR IMMEDIATE RELEASE – Nov. 6,2025 – LAKE ZURICH, Ill.— Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies is ...
Three lots (numbers 6133156, 6133194, 6133388) of Famotidine Injection are being recalled in the U.S. by Fresenius Kabi. Three lots (numbers 6133156, 6133194, 6133388) of Famotidine Injection are ...